With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.59702-07-7,1-Methylpiperazin-2-one,as a common compound, the synthetic route is as follows.
59702-07-7, To a vial were added methyl 6-bromoisoquinoline-3-carboxylate (83 mg, 0.31 mmol), 1- methylpiperazin-2-one (85 mg, 0.74 mmol), potassium phosphate, tribasic (175 mg, 0.81 mmol) and dioxane (2.5mL). The mixture was degassed by sparging with argon, RuPhos palladacycle Gen 4 pre-catalyst (22 mg, 8 mol%) was added and the vial was sealed and stirred at 100 C overnight. The reaction mixture was filtered, collected solids washed with EtOAc and purified on Si02 (0-10% methanol/dichloromethane) to give titled compound titled compound (20 mg 16%) as a yellow solid.
As the paragraph descriping shows that 59702-07-7 is playing an increasingly important role.
Reference£º
Patent; NURIX THERAPEUTICS, INC.; BARSANTI, Paul A.; BENCE, Neil F.; GOSLING, Jennifa; SAHA, Anjanabha; TAHERBHOY, Asad M.; ZAPF, Christoph W.; BOYLE, Kathleen; CARDOZO, Mario; MIHALIC, Jeffrey; LAWRENZ, Morgan; GALLOP, Mark; BRUFFEY, Jilliane; CUMMINS, Thomas; ROBBINS, Daniel; TANAKA, Hiroko; WANG, Chenbo; COHEN, Frederick; PALMER, Wylie; SANDS, Arthur T.; SHUNATONA, Hunter; (968 pag.)WO2019/148005; (2019); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics